BCAXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Bicara Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$17.47+0.69 (+4.11%)
Close on Oct 19, 2026
- Market cap
- $1.19B
- P/E (TTM)
- –
- Dividend yield
- –
Bicara Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Bicara Therapeutics | Industry median |
|---|---|---|
| Market Cap | $1.16B | $166.30M |
| Enterprise Value | $658.78M | $88.19M |
| PB Ratio | 2.47 | 2.03 |
| P/TBV Ratio | 2.47 | 2.29 |
Income (trailing twelve months)
| Measure | Bicara Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$201.99M | -$21.40M |
| Pretax Income | -$185.16M | -$14.34M |
| Net Income | -$185.36M | -$22.46M |
| EBITDA | -$201.99M | -$16.91M |
Returns
| Measure | Bicara Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -41.0% | -53.2% |
| Return on Assets (ROA) | -38.4% | -40.9% |
| Return on Capital Employed (ROCE) | -43.1% | -38.1% |
Balance sheet
| Measure | Bicara Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $497.26M | $61.43M |
| Net Cash (Debt) | $497.26M | $15.35M |
| Net Cash Per Share | $7.51 | $0.66 |
| Equity (Book Value) | $468.77M | $49.09M |
| Book Value Per Share | $7.08 | $1.37 |
| Tangible Book Value | $468.77M | $23.52M |
| Working Capital | $460.35M | $76.81M |
Financial position
| Measure | Bicara Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 11.59 | 3.34 |
| Quick Ratio | 11.44 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Bicara Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$134.85M | -$12.35M |
| Capital Expenditures | -$400.00K | -$1.08M |
| Free Cash Flow | -$135.25M | -$20.22M |
| FCF Per Share | -$2.04 | -$0.42 |
Efficiency
| Measure | Bicara Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$1.80M | -$703.34K |
| Employee Count | 103 | 74 |
Dividends and yields
| Measure | Bicara Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -16.0% | -23.3% |
| FCF Yield | -11.7% | -8.72% |
| Buyback Yield | -16.5% | -0.59% |
| Shareholder Yield | -16.5% | 0.00% |
Shares
| Measure | Bicara Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 66,172,900 | 58,127,000 |
| Shares Change (QoQ) | 0.59% | 0.54% |
| Float | 49,173,100 | 49,136,700 |
| Shares Held by Insiders | 25.7% | 11.6% |
| Shares Held by Institutions | 105.5% | 59.4% |
Taxes
| Measure | Bicara Therapeutics | Industry median |
|---|---|---|
| Income Tax | $206.00K | $79.87K |
Scores
| Measure | Bicara Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 14.45 | -0.22 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Bicara Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.